Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

  • STATUS
    Recruiting
  • End date
    Jul 1, 2027
  • participants needed
    40
  • sponsor
    Fred Hutchinson Cancer Center
Send
Updated on 29 April 2022
See if I qualify
treatment regimen
bone marrow procedure
primary cancer

Summary

This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating patients with nonmalignant (non-cancerous) diseases. Hematopoietic cell transplantation has been shown to be curative for many patients with nonmalignant (non-cancerious) diseases such as primary immunodeficiency disorders, immune dysregulatory disorders, hemophagocytic lymphohistiocytosis, bone marrow failure syndromes, and hemoglobinopathies. Powerful chemotherapy drugs are often used to condition the patient before infusion of the new healthy donor cells. The purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which doesn't work properly in order to make way for the new healthy donor cells which functions normally. Although effective in curing the patient's disease, many hematopoietic cell transplantation regimens use intensive chemotherapy which can be quite toxic, have significant side effects, and can potentially be life-threatening. Investigators are investigating whether a new conditioning regimen that uses less intensive drugs (treosulfan, thiotepa, and fludarabine phosphate) results in new blood-forming cells (engraftment) of the new donor cells without increased toxicities in patients with nonmalignant (non-cancerous) diseases.

Description

OUTLINE

Patients receive thiotepa intravenously (IV) twice daily (BID) on day -7, treosulfan IV on days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.

After completion of study treatment, patients are followed up at 1 year and then annually thereafter.

Details
Condition Non-Neoplastic Hematologic and Lymphocytic Disorder
Treatment fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, treosulfan, thiotepa, Rabbit Anti-thymocyte Globulin
Clinical Study IdentifierNCT03980769
SponsorFred Hutchinson Cancer Center
Last Modified on29 April 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patient with nonmalignant disease treatable by allogenic HCT
Patient with a nonmalignant disease that is not clearly defined (a patient with a non-malignant disease HCT for whom a genetic mutation responsible for their non-malignant disease phenotype has not been identified) are eligible for the study following discussion with and approval by the protocol principal investigator (PI) (Dr. Lauri Burroughs)
DONOR: Human leukocyte antigen (HLA)-identical related donor OR unrelated donor matched for HLA-A, B, C, DRB1 and DQB1 or mismatched for a single allele at HLA-A, B, C, or a single DQB1 antigen or allele mismatch by high resolution deoxyribonucleic acid (DNA) typing
DONOR: Bone marrow is the preferred cell source (when feasible). However, peripheral blood stem cells (PBSC) is also allowed and the PI may determine if PBSC is preferred for certain patients
The recommended total nucleated cell count (TNC) for bone marrow grafts is >= 4.0 x 10^8 TNC/kg (actual recipient weight)
The recommended CD34 cell count for PBSC grafts is >= 5 x 10^6 CD34/kg (actual recipient weight) and the recommended maximum CD34 cell count for PBSC grafts is 10 x 10^6 CD34/kg (actual recipient weight)
DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling
umbilical cord blood if the HLA-matched sibling umbilical cord blood was
collected and stored. The HLA-matched sibling bone marrow and cord blood would
be matched for HLA-A, B, C, DRB1 and DQB1

Exclusion Criteria

Patients with idiopathic aplastic anemia and Fanconi anemia; patients with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria (PNH) or inherited marrow failure syndromes (except Fanconi anemia) will be allowed
Impaired pulmonary function as evidenced by carbon monoxide diffusing capability (DLCO) corrected < 50% of predicted (or, if unable to perform pulmonary function tests, then oxygen [O2] saturation < 92% on room air)
Impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease. Patients with a shortening fraction of < 26% may be enrolled if approved by a cardiologist
Impaired renal function as evidenced by
Estimated creatinine clearance < 60 mL/min/1.73m^2 using either the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation for adult patients (>= 18 years old), or the updated Schwartz formula for pediatric patients (< 18 years old). If the estimated creatinine clearance is < 60 mL/min/1.73m^2, then renal function must be measured by 24-hour creatinine clearance, Iothalamate, Iohexol or nuclear GFR and the patient is excluded if their measured creatinine clearance is < 50 mL/min/1.73 m^2, OR
Serum creatinine > 2 x upper limit of normal, OR
Dialysis dependent
Active infectious disease requiring deferral of conditioning as recommended by an infectious disease specialist
Positive for HIV (human immunodeficiency virus)
Evidence of synthetic dysfunction or severe cirrhosis requiring deferral of
Females who are pregnant or breast-feeding
conditioning as recommended by a gastroenterology specialist
Known hypersensitivity to treosulfan, fludarabine, and/or thiotepa
DONOR: Donors deemed unable to undergo marrow harvesting of PBSC mobilization and leukapheresis
DONOR: HIV-positive donors
DONOR: Donors with active infectious hepatitis
DONOR: Female donor with positive pregnancy test
DONOR: Donors are excluded if the patient has an identified antibody against a donor-specific HLA locus as specified in standard practice
DONOR: HLA-matched sibling cord blood units that have not passed donor screening for infectious disease markers as recommended by the National Marrow Donor Project (NMDP) will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit. Cord blood units are presumed to be cytomegalovirus (CMV) negative regardless of serologic testing due to passive transmission of maternal CMV antibodies
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

treatment regimen
bone marrow procedure
primary cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note